secwatch.observer — SEC 8-K summary
======================================

Issuer:     Enliven Therapeutics, Inc. (ELVN)
CIK:        0001672619
Form:       8-K/A
Filed at:   2022-11-16T23:59:59+00:00
Accession:  0001193125-22-285963
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.85
Item codes: 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Imara sells PDE9 program (tovinontrine) to Cardurion for $35M upfront plus milestones
--------------------------------------------------------------------------------

- Upfront cash of $34.75M at closing plus $250K previously received; net proceeds ~$32.75M after ~$2M costs.
- Potential milestone payments: $10M for clinical proof-of-concept, $50M for regulatory/commercial events.
- Pro forma cash at Sep 30, 2022 rises to $82.2M; net loss for 9M 2022 falls from $30.7M to $13.0M.
- R&D expenses eliminated from $18.8M to $1.1M for 9M 2022 as sold asset costs are removed.
- Imara retains no further involvement in development or commercialization of the sold assets.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1672619/000119312522285963/0001193125-22-285963-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1672619/000119312522285963/d408792d8ka.htm
  HTML page:      https://secwatch.observer/filing/0001193125-22-285963

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer